Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report

IntroductionX-linked hypophosphatemia (XLH) is the most prevalent type of heritable fibroblast growth factor 23 (FGF23)-related hypophosphatemic rickets. Recently, anti-FGF23 antibody, burosumab, has become clinically available. We herein report a patient with adult XLH and tertiary hyperparathyroid...

Full description

Bibliographic Details
Main Authors: Yuichi Takashi, Kyoko Toyokawa, Naoki Oda, Yoshimi Muta, Hisashi Yokomizo, Seiji Fukumoto, Daiji Kawanami
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Endocrinology
Subjects:
X-linked hypophosphatemia
tertiary hyperparathyroidism
fibroblast growth factor 23
parathyroid hormone
burosumab
evocalcet
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.1004624/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.1004624/full

Similar Items